Q-Line Biotech IPO

Listed SME
Min Investment
₹2,74,400
800 Shares
Min Investment
₹2,74,400 · 800 Shares
Price Band ₹326–343
Lot Size 400 shares
Issue Size ₹214 Cr
Listed At ₹452.00 +31.8%
Subscribed 102.48×
Listed On NSE SME

Q-Line Biotech IPO Listing Day Performance

Q-Line Biotech listed on NSE SME on 29 May 2026 at ₹452.00, a 31.78% premium over the issue price of ₹343. A retail investor allotted the minimum application of 800 shares (2 lots) gained ₹87,200 at the listing price.

Issue price
₹343
upper band
Listing price
₹452.00
pre-open auction
Listing gain
+31.78%
+₹109 per share
Profit per application
+₹87,200
800 shares

GMP vs actual listing

Last GMP before listing₹125 (+36.4%)
GMP-implied listing₹468
Actual listing₹452.00
Difference−₹16 (−3.4%)

Demand going into listing

Subscribed overall102.48×
QIB123.94×
NII146.33×
Retail71.42×
Listing price = opening price from the exchange's pre-open call auction on listing day. Watch live price

Market Sentiment

Grey Market Premium What is GMP?
+₹125
+36.4% ▲ ₹5 since last update
Est. listing ₹468
Upper price ₹343
GMP range ₹99 – ₹132
21 May · ₹125 28 May · ₹125
Updated 28 May, 8:35 pm IST Unofficial grey-market data
GMP estimate ₹468
Actual listing ₹452
Listed below the GMP estimate by ₹16 (-3.4%)
Subscription Status
QIB
123.94x
NII
146.33x
bNII (>10L)
178.82x
sNII (2-10L)
81.35x
Retail
71.42x
Total
102.48x
Updated: May 25, 2026 5:01 pm IST
Analysis Score 70 / 100
Data: 80%
GMP Score · 44% weight 68
Subscription Score · 38% weight 75
Financial Health · 19% weight 66
Weighted average of the parts above; updates as GMP and subscription change. not investment advice.

IPO Details

Price Band₹326–343 per equity share
Face Value₹10 Per Equity Share
Lot Size 400 shares (Min 2 lots · ₹2,74,400)
Total Issue Size ₹214.00 crore
Fresh IssueEntire issue — no offer for sale, so all proceeds go to the company
Issue TypeBook build Issue
Lead Managers Hem Securities Ltd. , Share India Capital Services Pvt. Ltd.
Registrar Purva Sharegistry (India) Pvt.Limited.
Listing atNSE SME
NSE SymbolQLINE
ISININE1G2W01011
Listing Price₹452.00
Listing Gain+31.78%

Day-wise Subscription (times subscribed)

QIB
NII
Retail
Total
Each panel has its own scale.
Category Day 1 Day 2 Day 3 Day 5
QIB 4.15x 5.19x 5.19x 123.94x
NII 5.24x 15.96x 15.96x 146.33x
bNII > ₹10L 5.84x 18.49x 18.49x 178.82x
sNII 2-10L 4.03x 10.90x 10.90x 81.35x
Retail 3.61x 9.92x 9.92x 71.42x
Total 3.82x 9.17x 9.17x 102.48x

Market Lot Size

Category Lots Shares Amount (₹)
Retail Minimum 2 800 ₹2,74,400
Retail Maximum 2 800 ₹2,74,400
S-HNI Minimum 3 1,200 ₹4,11,600
S-HNI Maximum 7 2,800 ₹9,60,400
B-HNI Minimum 8 3,200 ₹10,97,600

IPO Reservation

QIB 20% NII 15% Retail 35% Anchor 30%
Category Shares Offered Shares %
QIB11,88,00020.00%
NII (HNI)8,91,60015.01%
bNII > ₹10L5,94,40010.01%
sNII < ₹10L2,97,2005.00%
Retail20,79,20035.00%
Anchor17,81,20029.99%
Total59,40,000

Financial Analysis

Financial Data

ROE
17.66%
ROCE
23.74%
Debt/Equity
0.87
NAV/Share
₹120.60
Revenue Growth
56.25%
Profit Margin
8.72%

Financial Performance

2025 vs 2024 Revenue +56.3% Profit (PAT) −18.3% Total Assets +34.3%
Metric 2023 2024 2025 Dec 2025
Revenue 184.81 206.45 322.58 236.50
Expense 154.97 175.85 261.43 186.96
Profit (PAT) 32.10 34.44 28.13 38.69
Total Assets 251.58 339.25 455.49 561.34
Values in Crores (₹)

Peer Comparison

Company EPS P/E
Powerica Limited 15.26 24.45
Cummins India Limited 72.15 64.13
Kirloskar Oil Engines Limited 33.71 43.24
NTPC Green Energy Limited 0.67 129.40
Acme Solar Holdings Limited 4.55 50.74
Adani Green Energy Limited 8.37 101.53
Peer median P/E 57.4x across 6 listed peers

Promoters & Holding Pattern

Promoters: Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal

Shareholding No. of Shares Holding %
Promoter Holding Pre Issue 1,70,74,999 96.77%

Strengths & Risks

Strengths
  • Heavily oversubscribed — 102.5x overall (so far).
  • Strong institutional (QIB) demand — 123.9x.
  • Revenue grew 56% in the latest reported year.
  • Solid profit margin — 8.7%.
  • Strong return on equity — 18%.
Risks & Concerns
  • Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.

From this issue's live data. Not investment advice — read the RHP.

Company Information

Q-Line Biotech at a glance

From the company's description: “Since its incorporation in 2013, Q-Line Biotech has been involved in the healthcare and diagnostic industry.”

Q-Line Biotech is raising ₹214 crore through an IPO on the NSE Emerge (SME). All of it is a fresh issue: there is no offer for sale, so every rupee raised goes to the company rather than to selling shareholders. Main stated uses of the fresh money: To meet Working Capital requirements (₹110 crore) and Repayment of certain borrowing availed by the Company, in part or full (₹90 crore).

Revenue went from ₹185 crore in 2023 to ₹323 crore in 2025, up 75% over 2 years. Profit after tax went from ₹32.1 crore to ₹28.13 crore, a net margin of 8.7% in the latest year.

Debt stands at 0.87 times equity.

Written from the issue's offer-document figures shown on this page. Not investment advice.

Company Contact Information

Q-Line Biotech Ltd., 298-281,, Transport Nagar,, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, 226012

Objects of the Issue

Purpose Amount (Cr)
To meet Working Capital requirements 110.00
Repayment of certain borrowing availed by the Company, in part or full 90.00
General Corporate Purpose -

Resources & Documents

Anchor Investors

Anchor Bidding Date
May 20, 2026
Shares Offered to Anchors
17,81,200
Lock-in End (30 Days, 50%)
June 22, 2026
Lock-in End (90 Days, 50%)
August 20, 2026

Q-Line Biotech IPO - Quick Take

Q-Line Biotech has set a price band of Rs 326–Rs 343 per share for an issue size of Rs 214 crore. The stock listed with a 31.78% gain versus its issue price on May 29, 2026.

The issue is promoted by Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal with Hem Securities Ltd., Share India Capital Services Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards to meet Working Capital requirements (Rs 110 crore) and repayment of certain borrowing availed by the Company, in part or full (Rs 90 crore).

On fundamentals, the company is posting revenue growth of 56.3%, a profit margin of 8.7%, return on equity of 17.7% in its most recent reported period. Listed peers in this segment include Powerica Limited (P/E 24.45x) and Cummins India Limited (P/E 64.13x) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.

On our data-signal score, the combined signals for this issue currently read strong — the composite picture tilts positive, though not without some caveats. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.

Q-Line Biotech IPO: Lead Manager & Registrar Track Record

How the firms running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Q-Line Biotech itself, so they describe what came before it.

SME IPOs, last 12 months
  • Q-Line Biotech listed at +31.8% on day one; the median of 193 listings was +1.5% (better than 81% of them).
  • Subscribed 102x against a median of 3.98x across 192 issues (higher than 77%).
  • Average listing-day move across all 194 SME listings we track: +11.6%.
Lead manager and registrar record on other IPOs we track
Firm Other IPOs Listed at / above issue Avg move Median
Hem Securities Ltd. Lead manager 14 0 MB · 14 SME 93% 13 of 14 +29.2% +16%
Share India Capital Services Pvt. Ltd. Lead manager 5 1 MB · 4 SME 80% 4 of 5 +5.8% +3%
Purva Sharegistry (India) Pvt.Limited. Registrar 8 0 MB · 8 SME 50% 4 of 8 Check allotment →
Recent listings managed by Hem Securities Ltd. (5)

Best: Vans Electroengineerings +90% · Weakest: Kasturi Metal Composite −1.3%

IPOListedListing-day move
HGS (India) 06 Nov 2026 +33.3%
Acme India Industries 09 Oct 2026 +12.8%
Vans Electroengineerings 07 Oct 2026 +90%
Century Business Media 21 Sep 2026 +0%
Raksan Transformers 18 Sep 2026 +0%
Recent listings managed by Share India Capital Services Pvt. Ltd. (5)

Best: Oneindig Technologies +25% · Weakest: GRE Renew Enertech −8.6%

IPOListedListing-day move
Pooja Logistics 30 Sep 2026 +2.6%
Oneindig Technologies 06 Aug 2026 +25%
Xtranet Technologies 30 Jul 2026 +7.1%
Happy Steels 16 Jul 2026 +3%
GRE Renew Enertech 21 Jan 2026 −8.6%
What a lead manager does

A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.

What a registrar does

Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.

Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.

Frequently Asked Questions

Q-Line Biotech listed at Rs 452.00 on 29 May 2026, against an issue price of Rs 343 — a 31.78% premium.

+31.78% at the listing price — Rs 109 per share, or Rs 87,200 on the minimum retail application of 800 shares.

The price band of Q-Line Biotech IPO is Rs 326 to Rs 343 per share. Face value is Rs 10 per share.

The total issue size of Q-Line Biotech IPO is Rs 214 crore, comprising fresh issue of Rs 214 crore.

The lot size of Q-Line Biotech IPO is 400 shares. The minimum application is 2 lots (800 shares), requiring an investment of Rs 2,74,400.

Q-Line Biotech IPO opens for subscription on May 21, 2026 and closes on May 25, 2026. Anchor investor bidding is scheduled for May 20, 2026.

The expected allotment date for Q-Line Biotech IPO is May 26, 2026. Refunds for unsuccessful applicants are expected on May 27, 2026.

Q-Line Biotech IPO is scheduled to list on May 29, 2026 on NSE. NSE symbol: QLINE, ISIN: INE1G2W01011.

The last GMP (Grey Market Premium) recorded for Q-Line Biotech IPO before listing was +Rs 125 (+36.4% over issue price). The shares actually listed at Rs 452 (+31.78% versus the issue price). GMP only estimates the listing price and stops mattering once the shares trade.

Q-Line Biotech IPO was subscribed 102.48 times overall by the close of bidding — retail at 71.42x, QIB at 123.94x, NII at 146.33x.

Based on the final retail subscription of 71.42x for Q-Line Biotech IPO, the estimated retail allotment probability is approximately 1.6%. This is a low probability — approximately 2 out of every 100 retail applications may receive allotment.

The registrar for Q-Line Biotech IPO is Purva Sharegistry (India) Pvt.Limited. After the allotment date, you can check your allotment status on the registrar's official website by entering your PAN, application number, or demat account details. Allotment status is also available on the BSE and NSE websites.

The book running lead manager(s) for Q-Line Biotech IPO are Hem Securities Ltd., Share India Capital Services Pvt. Ltd.

The promoter(s) of Q-Line Biotech are Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal.

Q-Line Biotech IPO GMP — What It Means

Its last GMP before listing was 36.4%. Of the 34 SME IPOs we have tracked with a final GMP of 25% or more, 34 listed above, 0 flat and 0 below the issue price; Q-Line Biotech listed 31.8% above its issue price.

See the full Q-Line Biotech GMP history and trend, or learn how grey market premium works and how reliable it is.

Related IPO

Same sector or same stage as Q-Line Biotech
Side by side: GMP, subscription, valuation, financials and listing performance.
0 Comments

No comments yet. Be the first to share your opinion!

GMPUpdate